Myeloma

[키워드] active treatment adrenal crisis Adrenal insufficiency Affect Anti-CD20 antibodies Anti-CD20 antibody Anti-viral antibodies antibody antibody formation Antibody titer Antibody titers Anticancer therapy B cells B-cell B.1.617.2 blockade Cancer CD4 CD8 Cell cellular Chemoimmunotherapy Chemotherapy Corticosteroids COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination COVID-19 vaccinations COVID-19 vaccine trials cross-reactive cytokine detectable develop dose doses effector cells Endocrine expressed follicular generate healthy donor healthy donors helper cells Humoral response hypoadrenalism Hypothesis IgG antibody titer immune Immunocompromised immunogenic immunogenicity immunogenicity, vaccine Immunotherapy intracellular cytokine staining Lymphocytes mRNA vaccine Multiple myeloma Myeloma n=36 no differences oncology patients Participants Patient Patients with cancer PD-1 peptide peptides Phase 3 profile Prophylactic RBD reactivity receiving Receptor binding domain Safe seronegative seronegative patient Side effect solid tumors spike Spike protein steroid Steroids Stress symptomatic T cell T cell response T cell responses T cells T follicular helper cells T-lymphocytes targeted therapy the SARS-CoV-2 therapy Treatment treatment groups tumors Two patient two patients vaccination Vaccinations Vaccine variant spike was measured were assessed were excluded wild-type WT spike
[DOI] 10.1136/jitc-2022-004766 PMC 바로가기 [Article Type] Article